Our high-quality products help to improve the health and wellbeing of people

Galderma has a significant history, starting in 1948, with a company called Spring Pharma in Olten, Switzerland. Later, in 1981, Nestle and L’Oreal formed Galderma as it is known today, which is the world’s number one dermatology company, focusing on acne, rosacea, psoriasis, and a number of other skin conditions.

For more than 30 years, Galderma has been dedicated to developing innovative medical dermatological solutions to help patients maintain healthy skin while improving their quality of life, and to help healthcare professionals worldwide. This while holding all products to the highest standard of safety and efficacy by partnering with dermatologists and other healthcare professionals in the field.

Prohealth is the exclusive distributor for Galderma Rx and A&C divisions in Malta, providing doctors and patients with products such as Epiduo, Soolantra, Etrivex, Differin, Loceryl, Rozex, and Tetralysal.

Restylane is a product that is developed by Galderma. Galderma carries out constant research and development programs to ensure the very best in safety and quality – in fact, Restylane is proven to be safe and effective, as well as a long-lasting treatment, with fillers and skin boosters for smoothing out facial lines, and wrinkles, creating fuller lips, and helping shape facial contours.

Restylane is a natural clear gel that can be injected under the skin surface for a result that usually lasts between 6 to 12 months. Based on hyaluronic acid that is similar to the body’s natural hyaluronic acid, Restylane helps restore volume and structure to the skin without affecting facial expressions nor facial movement.

Chemist Azevedo, known today as Grupo Azevedos, was founded in 1775. The company is the first Portuguese developer and producer of medicines, and has always been at the forefront of development within the pharmaceutical field.
Grupo Azevedos produced the first penicillin ointment, developed the very first antibiotic against the Typhus Fever, as well as the first Poliomyelitis vaccine in Portugal.

This is a company that strives towards loyalty and innovation, helping to set new standards in the pharmaceutical industry. Grupo Azevedos values assertiveness, honesty, respect, partnership, and professionalism.

A family owned company based in Jaworzno, Poland, ICB Pharma is a leader when it comes to both quality and efficacy in the healthcare and sanitary hygiene fields.

Using its own research and development laboratory, ICB Pharma strives to continuously develop better formulation enhancements within the area of “quasi-pharma”, and sanitary hygiene products. These are based on a unique solid core micro and nano encapsulation technology.

ICB Pharma export their products to countries all around the world, with Prohealth in charge of distributing Nitolic to the Maltese market. Nitolic is a specific formula that targets and completely eliminates head lice.

An Italian company based in Giammoro (ME), Italy, Laboratori PLANTS was founded in 1989. The company specialises in the manufacture of different forms of liquid and solid oral food supplements, including probiotics.

Laboratori PLANTS is dedicated to developing new and improved techniques in the field of pharmaceutical food supplements, applying knowledge gained through extensive research and innovation while using the latest technologies. The best quality is ensured thanks to constant physical-chemical, and microbiological analyses on all products – this includes compatibility testing with packaging materials.

Laboratori PLANTS entrusted Prohealth to distribute Clinflor in Malta, a unique blend of probiotics which include Saccharomyces and Lactobacilli. Clinflor helps replenish and balance natural bacteria in the gut.

Rowex is a company on a mission to remain one of the leading contenders in the pharmaceutical field, and to strengthen its global presence. It strives for these goals by adhering to a strict quality assurance policy, with laboratories that meet the highest in technological standards. Rowex products are currently available in over 70 countries.

Rowa is the parent company of Rowex Ltd, which is the company’s Irish Marketing division, established in 1993. Rowex is a forward-thinking, innovative company that aims to continue developing and manufacturing high-quality but affordable medicines which are available to everyone.

Rowex owes its worldwide success to the fact that each product satisfies strict standards.

Natiris, founded in 1971, is a nutritional supplement innovator and manufacturer based in Sintra, Portugal. The company prides itself on its dedication to providing products of high quality, efficacy and safety, which is based on its team’s rigorous research.

Due to its tendency to anticipate trends, as well as responding proactively to the various needs of the market, in the past 45 years, Natiris has established itself as a leader that is constantly developing its skills while generating competitive advantages within the field of nutritional supplements.

Natiris products are exported to a number of countries, including Malta. Prohealth has been entrusted with the distribution of supplements such as the CEREBRUM range, and JOINTFLEX to Maltese pharmacies.

Founded in 1915 in Genoa, Italy, PIAM is one of the contemporary leaders in the field of common and rare illnesses. The company’s dedication towards the incorporation of ethical measures in its research and production process is imperative in making PIAM a company well known for quality.

PIAM combines excellence with the guarantee for patient satisfaction, as well as passion and innovation, ensuring that patients are well taken care of and safe.

One of their better known products is Muciclar. Taken either as Capsules or in syrup form, Muciclar is used to aid with acute and chronic bronchopulmonary diseases, usually connected to abnormal mucus secretion as well as impaired mucus transport.

Ursapharm is a German company turned global, founded in 1974. For over 30 years now, the company has striven to turn innovative pharmaceutical concepts into successful medicinal products and medical devices. Thanks to its vast portfolio, today, Ursapharm is one of the market leaders in the field of ophthalmology in Germany, and in the area of dry eye syndrome in Europe.

Adhering to national and international quality standards is paramount during product development, which is why Ursapharm maintains very strict criteria for all their products, which include Hysan nasal sprays, Hylo eye lubricants, and Azelastin-POS Eye Drops to treat acute, and chronic allergic conjunctivitis.

Its patented COMOD™ delivery system allows Ursapharm to provide preservative-free eye drops and nasal sprays which remain sterile for up to 6 months after first opening, making these products safer and more cost effective to our patients.

Thanks to a dedicated group of staff, as well as continuous investment and research to remain up-to-date when it comes to production facilities and the implementation of environmentally compliant techniques, Ursapharm continues to be a reliable partner within the healthcare and contract manufacture fields.

Reig Jofre is a Spanish pharmaceutical company, originating in Barcelona. The company is dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre was founded in 1929 by Ramon Reig Jofre. The company is currently still family run despite expanding significantly over recent years. Reig Jofre now employs more than 1,000 employees across 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden) and is distributed in 70 countries around the world. Reig Jofre has a broad portfolio of products that can be divided into three categories: Pharmaceutical Technology products (antibiotics and injectables), Speciality Products in particular therapeutic areas and Consumer products which are food supplements in nature.

Reig Jofre has a highly experienced R & D team which is composed of 47 researchers with experience in the following fields:

• Bioequivalence studies
• Clinical pharmacokinetics and bioavailability studies
• Drug interaction studies
• Preclinical pharmacokinetics
• Preclinical toxicokinetics
• Analysis and identification of metabolites

Based on this experience, Reig Jofre develops new pharmaceutical products or variations on known active ingredients in order to modify their release, improve their dosage and obtain new routes of administration or indications. These developments are particularly strong in the fields on dermatology, gynaecology and respiratory treatment. This high level of professional commitment is also translated into product development, manufacture of pre-clinical batches, qualirt control and assurance, regulatory compliance and validation of commercial batches, guaranteeing safe, effective and high-quality medications to their clients worldwide.

Bifodan is an innovative and reliable supplier of finished probiotic solutions of high quality and documented stability. Their products are classified and documented as dietary food supplements and their customers are B2B nutritional/dietary supplement distributors, pharmacy chains, and drugstores worldwide.

Bifodan was founded in 1992 by the Danish dairy cooperative, Enigheden. Enigheden was the first Danish dairy to work with probiotics, and also the first to market a branded yogurt product with lactobacillus acidophilus in 1938, A-38®. Rooted in their long-standing experience and knowledge about probiotic research, development and processing, Bifodan reaches for the sky as they continue to apply their technology platform and know-how to the benefit of their partners.

For more than 25 years Bifodan has been dedicated to probiotics and on optimizing the complicated processing of probiotic bacteria. Based on clinically documented probiotic strains, they develop innovative formulations and dosage forms that satisfy true market needs.

The name Krewel Meuselbach stands for two companies with an impressive tradition in the German pharmaceutical world: Krewel Werke and Meuselbach-Pharma. The merger of these two tradition-steeped pharmaceutical companies in 1996 gave birth to Krewel Meuselbach. Great creativity and innovative spirit have always shaped the history of both companies. The history of Krewel Werke begins in 1893 in Cologne, when the pharmacy Apotheker Krewel & Co. was founded by the pharmacist August Krewel. In 1922, Dr phil. Ernst Georg Blank took over management of the company and began production of medicinal preparations which were very successful in the German market. The foundation stone for the Krewel production facilities was laid. Following this, Dr Blank expanded the range of indications and developed other preparations of high pharmaceutical and therapeutic quality, some of which are still used in therapy today.

Krewel Meuselbach is now known as an internationally operating family company with its own production facilities and strong commitment to its German roots. These strong roots give the company strength to succeed and grow in the dynamic pharmaceutical market with its global challenges. The company therefore emphasizes German quality and strong traditions as the basis of their success. Krewel’s expertise and experience gathered over the years generates the ideas and innovations that give their products that certain touch: the most modern health products developed with the knowledge of generations – highly effective and well tolerated.

 Krewel Meuselbach’s competitive position is based on the high quality of their medicinal products and the innovative formulation development of established active ingredients. However, a quite essential aspect of the company’s philosophy is based on herbal alternatives. Long years of research and developing gentle production processes for herbal medicinal products have made the manufacture of particularly well-tolerated phytopharmaceuticals possible. For a long time, Krewel Meuselbach has been setting benchmarks in the standardisation of herbal extracts and innovative galenic processing, and in maintaining a consistently high bioavailability of the active ingredients.

Salvat was founded in Barcelona in 1955. Innovation is the fuel that drives their business. Whether through projects stemming from the company’s in-house R&D or by partnering with public and private research groups, research is focused around three therapeutic areas: Otolaryngology, Ophthalmology and Gastroenterology. All products developed by Salvat share a common goal, to provide innovative solutions to improve people’s quality of life. Salvat is a world leader, particularly in otolaryngology. Constant innovation in the field has allowed Salvat to lead the Spanish market and to achieve constant growth in other geographies. In 1982, with the understanding that growth opportunities would come from beyond local borders, the International Division was launched. Today, international sales represent approximately 40% of the business and are one of Salvat’s major growth pillars.

Salvat has offices and manufacturing facilities in Barcelona, Madrid and Miami. Salvat also has partners with licenses to market their products in Europe, United States, Canada, Mexico, South America, North of Africa, Middle East, India, South East Asia, China and South Korea.

“We share a deep commitment to innovation and employment generation. By always putting patients first, we can achieve our primary objective: contribution to a healthier and happier life”

Javier Peris, President